title: Laropiprant in combination with extended-release niacin does not alter urine 11-dehydrothromboxane B2, a marker of in vivo platelet function, in healthy, hypercholesterolemic, and diabetic subjects.
abstract: Laropiprant, an antagonist of the PGD(2) receptor, DP1, is effective in reducing the flushing symptoms associated with extended-release (ER) niacin and thereby improves the tolerability of niacin therapy for dyslipidemia. Because PGD(2) has been reported to inhibit platelet aggregation in vitro, it has been speculated that antagonism of DP1 may enhance platelet reactivity. Three clinical studies evaluated the potential effect of laropiprant, with or without coadministration of ER niacin, on in vivo platelet function in healthy subjects and hypercholesterolemic or diabetic subjects by measuring urinary levels of 11-dehydrothromboxane B(2) (11-dTxB(2)), a marker of in vivo platelet activation. Following 7 days of multiple-dose administration, coadministration of laropiprant with ER niacin did not increase urinary 11-dTxB(2) levels compared to ER niacin alone in healthy, hypercholesterolemic, or diabetic subjects. In hypercholesterolemic and diabetic subjects, laropiprant did not increase urinary 11-dTxB(2) levels compared to placebo. These results demonstrate that laropiprant does not enhance in vivo platelet reactivity, either alone or in combination with niacin.
authors.affiliation: Department of Clinical Pharmacology, Merck Research Laboratories, Rahway, New Jersey, USA.
authors.forename: Brett
authors.initials: B
authors.lastname: Lauring
authors.forename: Victor
authors.initials: V
authors.lastname: Dishy
authors.forename: Wen-Lin
authors.initials: WL
authors.lastname: Luo
authors.forename: Omar
authors.initials: O
authors.lastname: Laterza
authors.forename: Jaclyn
authors.initials: J
authors.lastname: Patterson
authors.forename: Josee
authors.initials: J
authors.lastname: Cote
authors.forename: Alice
authors.initials: A
authors.lastname: Chao
authors.forename: Patrick
authors.initials: P
authors.lastname: Larson
authors.forename: Maria
authors.initials: M
authors.lastname: Gutierrez
authors.forename: John A
authors.initials: JA
authors.lastname: Wagner
authors.forename: Eseng
authors.initials: E
authors.lastname: Lai
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000652:urine; D001792:Blood Platelets / Q000187:drug effects* / Q000378:metabolism; D018592:Cross-Over Studies; D003692:Delayed-Action Preparations; D003920:Diabetes Mellitus / Q000097:blood*; D004311:Double-Blind Method; D011464:Epoprostenol / Q000378:metabolism; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood*; D007211:Indoles / Q000009:adverse effects / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D009525:Niacin / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D015539:Platelet Activation; D015230:Prostaglandin D2 / Q000378:metabolism; D011971:Receptors, Immunologic / Q000037:antagonists & inhibitors*; D011982:Receptors, Prostaglandin / Q000037:antagonists & inhibitors*; D013929:Thromboxane B2 / Q000031:analogs & derivatives* / Q000378:metabolism / Q000652:urine; D055815:Young Adult
chemical_list: D015415:Biomarkers; D003692:Delayed-Action Preparations; D007211:Indoles; C518174:MK-0524; D011971:Receptors, Immunologic; D011982:Receptors, Prostaglandin; D009525:Niacin; D013929:Thromboxane B2; C049235:11-dehydro-thromboxane B2; D011464:Epoprostenol; D015230:Prostaglandin D2; C036293:prostaglandin D2 receptor